LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

LLY

1,023.96

-2.57%↓

JNJ

247.71

-0.29%↓

ABBV

232.89

+0.39%↑

NVS

167.23

-0.65%↓

MRK

121.12

-2.1%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Отворен

СекторЗдравеопазване

18.17 -4.97

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.47

Максимум

19.12

Ключови измерители
By Trading Economics
Приходи	4.8M -36M
Продажби	6.1M 116M
Марж на печалбата	-30.977
Служители	1,869
EBITDA	24M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+87.98% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-800M 2.2B
Предишно отваряне	23.14
Предишно затваряне	18.17

Настроения в новините

By Acuity

44%

56%

129 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.03.2026 г., 23:35 ч. UTC

Значими събития в новините

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1.03.2026 г., 23:19 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1.03.2026 г., 23:14 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1.03.2026 г., 22:55 ч. UTC

Значими събития в новините

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1.03.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1.03.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1.03.2026 г., 22:38 ч. UTC

Пазарно говорене

Значими събития в новините

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1.03.2026 г., 22:21 ч. UTC

Печалби

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1.03.2026 г., 22:17 ч. UTC

Пазарно говорене

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Значими събития в новините

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Значими събития в новините

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1.03.2026 г., 21:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1.03.2026 г., 21:30 ч. UTC

Пазарно говорене

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1.03.2026 г., 21:27 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1.03.2026 г., 21:19 ч. UTC

Пазарно говорене

Значими събития в новините

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1.03.2026 г., 20:58 ч. UTC

Пазарно говорене

Значими събития в новините

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1.03.2026 г., 20:40 ч. UTC

Пазарно говорене

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1.03.2026 г., 20:24 ч. UTC

Пазарно говорене

Значими събития в новините

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

87.98% нагоре

12-месечна прогноза

Среден 36.13 USD 87.98%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

129 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.